Author technical setup chart
Sangamo (SGMO) is well-situated for the remainder of 2020 after the Biogen (BIIB) collaboration. 1Q20 cash plus the Biogen proceeds brought available cash to over $700 million. Sangamo C20 guidance for non-GAAP operating expenses (opex less stock compensation expense) is $245 to 260 million. Approximately $20-25 million of that research will be reimbursed by collaboration partners.
Biogen Collaboration
Global Collaboration Agreement With BIIB To Develop Therapies For Neurological Disorders Closes; SGMO Received $350MM Q2. SGMO recently closed the collaboration agreement (initially announced on February 27, 2020) with